Outcomes of CD19 targeted CAR T-cell Therapy for Patients with Reduced Renal Function Including Dialysis

Patients with renal impairment (RI) are typically excluded from trials evaluating chimeric antigen receptor (CAR) T-cell therapies. We evaluated the outcomes of patients with RI receiving standard-of-care (SOC) CAR T-cell therapy for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL).